# Tinea Cruris

Confirm dermatophyte infection when morphology is atypical, recurrent, extensive, or treatment-refractory; treat limited disease with topical antifungal monotherapy, identify pedal or nail reservoirs, and escalate persistent disease to culture, speciation, susceptibility testing, and systemic therapy planning.

**Clinical question:** How should clinicians confirm, treat, and escalate suspected tinea cruris that is extensive, recurrent, or unresponsive to topical therapy?

Updated: 2026-09-15T23:53:14.307114+00:00

## What matters in practice
- Obtain a KOH preparation from the active advancing border when the diagnosis is uncertain, disease is recurrent or extensive, or empiric treatment has failed; hyphae support dermatophyte infection. [9][22]
- For mild, non-extensive tinea cruris, use topical antifungal monotherapy; allylamines and azoles are standard options, generally applied once or twice daily for 2–4 weeks. [18][19]
- Avoid topical corticosteroids, including antifungal-corticosteroid combinations, in suspected dermatophyte infection because they can worsen or mask tinea and complicate recognition of resistant disease. [20][21]
- Examine and address concurrent tinea pedis and onychomycosis, which can maintain reinoculation and prevent durable clearance of groin disease. [9][22]
- For persistent or severe disease, obtain fungal culture with dermatophyte identification and antifungal susceptibility testing when available; resistant T. indotineae may not respond to topical agents or oral terbinafine. [21]

## Confirm dermatophyte infection before escalating treatment

Testing is most valuable when morphology, response, or epidemiology makes a clinical diagnosis unreliable.

A clinically typical, localized groin eruption may be managed empirically, but perform direct microscopy when the eruption is atypical, recurrent, extensive, steroid-modified, or has not improved with an adequate topical course. Collect scale from the active peripheral border rather than macerated central skin; visible hyphae on potassium hydroxide (KOH) examination support dermatophyte infection. [9][22]

A negative KOH result does not exclude tinea when sampling is poor or prior antifungal therapy has reduced recoverable material. In tinea pedis studies, KOH sensitivity and specificity varied substantially according to the reference standard; discordance among clinical assessment, KOH, and culture can reflect sampling error and culture-handling limitations. Repeat sampling from an untreated active edge or send fungal culture when the result will change treatment. [10][11]

Culture is most useful before systemic therapy for recalcitrant disease, before labeling an eruption antifungal-resistant, and when an emerging dermatophyte is plausible. Request dermatophyte identification and antifungal susceptibility testing through a laboratory able to perform these services; species identification and susceptibility testing guide therapy in potentially resistant dermatophytosis. [21]
- Ask specifically about topical corticosteroid exposure, including combination products; altered morphology should prompt KOH and culture rather than escalation of steroid treatment. [20][21]
- Assess for extensive plaques involving trunk, face, extremities, groin, or anogenital skin; this distribution raises concern for emerging dermatophytes when disease is unusually inflammatory or treatment-refractory. [20][21]
- Ask about close skin-to-skin contact, affected contacts, travel or immigration involving South Asia, and animal exposure when culture is being pursued; these exposures can alter concern for T. indotineae or sexually associated Trichophyton mentagrophytes genotype VII (TMVII). [20][21]

*Tests and bedside discriminators for a groin eruption suspected to be tinea cruris. [9][20][21]*

| Finding or test | Interpretation | Next action |
| --- | --- | --- |
| KOH scraping from advancing border shows hyphae | Supports dermatophyte infection. [9] | Treat as tinea cruris; evaluate feet and nails for a reservoir. [9][22] |
| KOH negative but active scaly border persists or prior therapy confounds sampling | False-negative microscopy remains possible because sampling and test performance are imperfect. [10][11] | Repeat scraping from an active edge and obtain fungal culture if treatment escalation is contemplated. [10][21] |
| Coral-colored fluorescence under ultraviolet light | Favors erythrasma over dermatophyte infection. [9] | Redirect treatment away from dermatophyte-focused therapy. [9] |
| Extensive, persistent disease despite topical therapy or oral terbinafine | Raises concern for resistant dermatophytosis, including T. indotineae. [21] | Obtain culture, species identification, and antifungal susceptibility testing when available; plan systemic therapy with attention to itraconazole limitations. [21] |

## Use distribution and targeted tests to separate common mimics

A groin eruption that is not dermatophyte infection should not receive prolonged antifungal escalation.

Prioritize candidal intertrigo, erythrasma, irritant or allergic contact dermatitis, psoriasis, seborrheic dermatitis, and secondary Candida infection in chronic groin disease. Diagnostic uncertainty should trigger KOH examination from the lesion edge; dermatophyte hyphae support tinea, whereas erythrasma is distinguished clinically by coral-colored fluorescence under ultraviolet light. [8][9]

In an obese patient with chronically moist, macerated folds, candidal superinfection may coexist with tinea cruris. If the eruption fails to clear, reassess the diagnosis and concurrent processes rather than assuming antifungal resistance; candidal intertrigo, dermatitis, and erythrasma require different management. [9]

Steroid exposure is a high-value discriminator. Topical corticosteroids, including fixed antifungal-corticosteroid products, can worsen dermatophyte infection and blunt its recognizable inflammatory border. Stop the steroid-containing product, obtain mycologic testing from active scale when feasible, and treat the confirmed infection with an antifungal regimen rather than continued anti-inflammatory monotherapy. [20][21]
- Do not equate symptomatic improvement during a topical corticosteroid course with fungal eradication; corticosteroid-containing combinations have not shown superior mycologic cure over antifungal treatment alone in low-quality evidence. [17]
- If a presumed dermatophyte eruption involves genital or anogenital skin and there is potential sexual transmission, consider TMVII and advise avoiding skin-to-skin contact with affected areas and avoiding shared personal items until symptoms resolve. [20]

*High-yield alternatives to tinea cruris and the discriminator that changes management. [8][9][20]*

| Alternative diagnosis | Discriminator | Management implication |
| --- | --- | --- |
| Erythrasma | Coral-colored fluorescence with ultraviolet light. [9] | Do not continue empiric dermatophyte escalation without reassessing the diagnosis. [9] |
| Candidal intertrigo | Chronic moist-fold disease, especially in obesity; may coexist with tinea. [9] | Address candidal involvement and fold moisture rather than attributing persistence solely to dermatophyte resistance. [9] |
| Irritant or allergic contact dermatitis | Compatible morphology with negative mycology or exposure-related distribution. [8][9] | Remove the offending exposure and avoid unnecessary prolonged antifungal treatment. [8][9] |
| Psoriasis or seborrheic dermatitis | Persistent intertriginous eruption without demonstrated hyphae. [8][9] | Reassess diagnosis before systemic antifungal therapy. [8][9] |
| Steroid-modified tinea | Current or recent topical corticosteroid or combination-product use with atypical eruption. [20][21] | Stop steroid-containing therapy, obtain KOH/culture when possible, and use antifungal-directed treatment. [20][21] |

## Treat limited disease with topical antifungal monotherapy

Topical treatment is preferred when disease is mild and non-extensive.

Use a topical antifungal cream for mild, non-extensive tinea cruris in adults or children. Allylamines, including terbinafine, butenafine, and naftifine, and azoles, including clotrimazole, miconazole, econazole, ketoconazole, oxiconazole, and sulconazole, are standard topical options; topical regimens are generally used once or twice daily for 2–4 weeks. [18][19]

Choose an agent according to formulary access, expected adherence, prior exposure, and labeled indication. Evidence from randomized trials supports topical terbinafine versus placebo for clinical cure in tinea corporis/cruris, and systematic-review evidence supports multiple topical antifungals, particularly azoles, for clinical and mycologic cure. [15][17]

Do not add a topical corticosteroid routinely. Combination steroid-antifungal therapy may reduce visible inflammation transiently, but available evidence found similar mycologic cure compared with antifungal alone and is of very low quality; CDC specifically advises avoiding corticosteroid products, including combination products, because they can worsen dermatophyte infection. [17][20]
- Naftifine 2% cream has FDA approval for tinea cruris caused by Trichophyton rubrum in adults; use according to the current product label. [2]
- Luliconazole 1% cream is FDA-approved for tinea cruris caused by T. rubrum or Epidermophyton floccosum in patients aged 18 years or older; use according to the current product label. [3]
- Reassess a patient with ongoing active scale, expanding border, or new sites after an adequate adherent topical course; obtain mycologic testing instead of repeatedly substituting empiric topical products. [21][22]

*Topical treatment selection for uncomplicated tinea cruris. [2][3][15][18][19]*

| Clinical situation | Preferred approach | Important limitation |
| --- | --- | --- |
| Mild, non-extensive disease | Topical antifungal monotherapy; allylamine or azole regimens are generally used once or twice daily for 2–4 weeks. [18][19] | Persistent active disease requires diagnostic reassessment, not indefinite empiric topical therapy. [21] |
| Adult with susceptible labeled organisms and access to naftifine | Naftifine 2% cream is FDA-approved for adult tinea cruris caused by T. rubrum. [2] | Use only within current labeling and reassess nonresponse. [2][21] |
| Adult with susceptible labeled organisms and access to luliconazole | Luliconazole 1% cream is FDA-approved for adult tinea cruris caused by T. rubrum or E. floccosum. [3] | Label indication is limited to patients aged 18 years and older. [3] |
| Marked inflammation after prior steroid exposure | Stop steroid-containing product and confirm dermatophyte infection with KOH/culture when feasible. [20][21] | Combination products can mask progression and worsen tinea. [20] |

## Find pedal, nail, contact, and moisture drivers of recurrence

Persistent groin disease may represent reinoculation rather than drug failure.

Examine toe webs, plantar surfaces, and toenails at the initial visit and at apparent treatment failure. Tinea pedis and onychomycosis commonly coexist with dermatophyte skin disease, and untreated nail infection can prevent complete clearance of tinea cruris through reinfection. [9][22]

For weeping or macerated groin lesions, use Burow solution compresses to dry the area before topical antifungal application. Avoid mixing nystatin powder directly with antifungal cream because the combination can form a gritty, irritating mixture; nystatin is relevant to Candida, not dermatophyte-directed therapy. [9]

When TMVII is suspected or confirmed, counsel patients to avoid direct skin-to-skin contact with affected areas and not share personal items until symptoms resolve. This organism can be sexually transmitted and may favor anogenital skin. [20]
- In recurrent disease, treat demonstrable tinea pedis and evaluate suspected onychomycosis rather than treating the groin as an isolated site. [9][22]
- If close contacts have compatible eruptions, assess them clinically because direct person-to-person spread contributes to dermatophyte transmission. [22]
- Do not use topical corticosteroid products to suppress recurrent itch while awaiting reassessment; this can worsen or obscure dermatophyte infection. [20]

*Actions that reduce persistence or reinoculation in tinea cruris. [9][20][22]*

| Potential driver | What to assess | Action |
| --- | --- | --- |
| Tinea pedis | Interdigital and plantar scale or maceration. [22] | Treat concurrent foot infection to reduce autoinoculation. [9][22] |
| Onychomycosis | Thickened, discolored, brittle toenails. [22][24] | Evaluate and treat confirmed nail disease when it is sustaining recurrent dermatophyte infection. [9] |
| Moist, weeping folds | Maceration or exudation. [9] | Use Burow solution compresses for drying before topical antifungal application. [9] |
| Potential sexual or household spread | Affected close contacts, skin-to-skin exposure, or shared personal items. [20][22] | Avoid skin-to-skin contact with affected lesions and avoid sharing personal items until symptom resolution. [20] |

## Escalate extensive, refractory, or suspected resistant tinea with mycology

Systemic treatment decisions should follow confirmation and resistance-oriented testing whenever possible.

Consider oral antifungal therapy when tinea cruris is resistant to topical treatment, when topical agents cannot be used, or when disease extent makes topical treatment impractical. Guidelines strongly recommend oral therapy for tinea corporis/cruris in patients unable to use or resistant to topical agents, while emphasizing that limited disease is generally managed topically. [13]

Before systemic escalation in refractory disease, obtain fungal culture and request species identification and antifungal susceptibility testing when available. T. indotineae can cause extensive plaques involving the trunk, extremities, groin, and face and often does not resolve with over-the-counter topical therapy or oral terbinafine. [21]

Itraconazole has been used successfully for T. indotineae and terbinafine-resistant T. rubrum, but resistant-disease management is not standardized in U.S. national guidelines. If itraconazole is selected, account for variable absorption, drug-drug interactions, insurance barriers, potentially prolonged treatment exceeding 6 weeks, and emerging itraconazole resistance; obtain specialist input when susceptibility testing, regimen selection, or drug-interaction management is needed. [21]
- Do not diagnose terbinafine resistance from persistent rash alone: verify ongoing dermatophyte infection and exclude dermatitis, erythrasma, candidal intertrigo, nonadherence, and an untreated foot or nail reservoir. [9][21]
- Consider T. indotineae particularly with refractory, extensive disease and travel or immigration linkage to South Asia. [20][21]
- Consider TMVII with anogenital-predominant tinea and potential sexual transmission; unlike T. indotineae, TMVII is described as generally susceptible to terbinafine first-line therapy. [20]

### When to refer

Refer to dermatology or infectious diseases for culture-confirmed or strongly suspected resistant dermatophytosis, disease requiring prolonged systemic therapy, inability to access species identification or susceptibility testing, or unresolved diagnostic uncertainty after KOH and culture. These scenarios require interpretation of species-level results, systemic-drug interaction review, and treatment adjustment when terbinafine or itraconazole failure occurs. [21]

*Escalation pathway for tinea cruris not controlled with topical therapy. [13][20][21]*

| Escalation trigger | Required evaluation | Management direction |
| --- | --- | --- |
| Topical treatment failure | Repeat KOH from active border; examine feet and nails; obtain fungal culture when systemic treatment is under consideration. [9][21] | Use oral antifungal therapy when topical resistance or inability to use topical treatment is established. [13] |
| Extensive or unusually inflammatory plaques | Culture with species identification and susceptibility testing when available. [21] | Evaluate for T. indotineae and avoid assuming oral terbinafine will be effective. [21] |
| Suspected terbinafine-resistant dermatophyte | Confirm organism and susceptibility profile when possible. [21] | Itraconazole has been used successfully, but manage absorption, interactions, prolonged-course needs, and emerging resistance. [21] |
| Anogenital disease with possible sexual spread | Obtain mycology and consider TMVII. [20] | Counsel against skin-to-skin contact with affected sites and sharing personal items until symptoms resolve. [20] |

## References
1. [PDF] Application Type Efficacy Supplement - FDA — www.fda.gov — https://www.fda.gov/media/111545/download
2. [PDF] Clinical Review - FDA — www.fda.gov — https://www.fda.gov/media/102199/download
3. [PDF] Cross Discipline Team Leader Review - FDA — www.fda.gov — https://www.fda.gov/media/111550/download
4. Dermatophyte infections - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/119
5. Re: Steroid modified tinea | The BMJ — www.bmj.com — https://www.bmj.com/content/356/bmj.j973/rr
6. Efficacy of Topical Antifungals in the Treatment of Dermatophytosis ... — jamanetwork.com — https://jamanetwork.com/HttpHandlers/ArticlePdfHandler.ashx?journal=DERM&pdfFileName=dpz120011_341_349.pdf
7. Management of tinea corporis, tinea cruris, and... : Indian Dermatology Online Journal — journals.lww.com — https://journals.lww.com/idoj/fulltext/2016/07020/management_of_tinea_corporis,_tinea_cruris,_and.2.aspx
8. Tinea Cruis: A Bothersome Male Condition - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1555415505003235
9. Tinea cruris - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/tinea-cruris
10. The Sensitivity and Specificity of Potassium Hydroxide Smear and Fungal Culture Relative to Clinical Assessment in the Evaluation of Tinea Pedis: A Pooled Analysis - Levitt - 2010 - Dermatology Research and Practice - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2010/764843
11. Frequency of Culture-Proven Dermatophyte Infection in Patients with Suspected Tinea Pedis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002962915341264
12. The Necessity of Culture for the Diagnosis of Tinea Pedis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002962915328470
13. Guidelines for the management of dermatomycosis (2019) — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15618
14. NEXTODERM: Consensus on Dermatophytosis Diagnosis and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/drp/1347872
15. Evidence‐based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review - Zuuren - 2015 - British Journal of Dermatology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.13441
16. Topical and oral treatments for fungal skin infections — wchh.onlinelibrary.wiley.com — https://wchh.onlinelibrary.wiley.com/doi/pdf/10.1002/psb.360
17. Topical antifungal treatments for tinea cruris and tinea corporis - El‐Gohary, M - 2014 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009992.pub2/full
18. Tinea Cruris - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK554602
19. Scenario: Management | Management | Fungal skin infection - body and groin | CKS | NICE — cks.nice.org.uk — https://cks.nice.org.uk/topics/fungal-skin-infection-body-groin/management/management
20. Notes from the Field: Trichophyton mentagrophytes Genotype VII — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/73/wr/mm7343a5.htm
21. Recognition of Antifungal-Resistant Dermatophytosis by Infectious ... — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/30/9/24-0118_article
22. Clinical Overview of Ringworm | Ringworm | CDC — www.cdc.gov — https://www.cdc.gov/ringworm/hcp/clinical-overview/index.html
23. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK132708
24. Ringworm Basics | Ringworm | CDC — www.cdc.gov — https://www.cdc.gov/ringworm/about/index.html

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.